Dr. Christiane Dings

Marconato M, Hackenbruch C, Jäger S, Göpel S, Kirieieva T, Gavrylov A, Fricke H, Hust M, Dübel S, Dings C, Lehr T, Cuevas M, Bitzer M, Klein C, Schwab M, Wirtz H, Schneider J, Bitter T, Frenzel A, Dhaen MA, Herrmann A, Jung G, Walz JS, Salih HR, Heitmann JS. Phase I study evaluating a monoclonal Fc-silenced SARS-CoV-2 antibody in patients with moderate-to-severe COVID-19. Clinical Therapeutics. 2026. doi:10.1016/j.clinthera.2026.01.004

Walle N, Dings C, Zaher O, Doerr AA, Peters B, Laschke MW, Lehr T, Menger MD, Schmidt PH, Meyer MR, Schaefer N. Does a carboxamide moiety alter the toxicokinetics of synthetic cannabinoids? A study after pulmonary and intravenous administration of cumyl-5F-P7AICA to pigs. Archives of Toxicology. 2025. doi:10.1007/s00204-024-03906-z

Doerr AA, Dings C, Zaher O, Nordmeier F, Walle N, Laschke MW, Menger MD, Schmidt PH, Meyer MR, Lehr T, Schaefer N. Toxicokinetic modelling of the synthetic cannabinoid 5F-MDMB-P7AICA and its main metabolite in pigs following pulmonary administration. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16340

Ruiz Seco MP, Paño Pardo JR, Schoergenhofer C, Dings C, Lehr T, Herth F, Krendyukov A, Straub C, Kappler M, Jilma B, Fricke H, Pardo J, de Miguel D, Thiemann M, Bergmann M, Walczak H, Hoeger T. Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102879

Dings C, Selzer D, Bragazzi NL, Möhler E, Wenning M, Gehrke T, Richter U, Nonnenmacher A, Brinkmann F, Rothoeft T, Zemlin M, Lücke T, Lehr T. Effect of vaccinations and school restrictions on the spread of COVID-19 in different age groups in Germany. Infectious Disease Modelling. 2024. doi:10.1016/j.idm.2024.07.004

Dings C, Lehr T, Vojnar B, Gaik C, Koch T, Eberhart LHJ, Huljic-Lankinen S, Murst M, Kreuer S. Population kinetic/pharmacodynamic modelling of the haemodynamic effects of cafedrine/theodrenaline (Akrinor) under general anaesthesia. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16083

Rothoeft T, Brinkmann F, Maier C, Selzer D, Dings C, Kuehn A, Möhler E, Grote H, Nonnenmacher A, Wenning M, Zemlin M, Richter U, Lehr T, Lücke T. Motivations for adolescent COVID-19 vaccination: A comparative study of adolescent and caregiver perspectives in Germany. Children. 2023. doi:10.3390/children10121890

Sager P, Kaiser A, Schumann S, Ludescher B, Niedermaier M, Schmidt I, Och K, Dings C, Lehr T, Brysch W. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: A multicentre, randomised double-blind, placebo-controlled phase 2a trial. The Lancet Regional Health – Europe. 2023. doi:10.1016/j.lanepe.2023.100810

Türk D, Scherer N, Selzer D, Dings C, Hanke N, Dallmann R, Schwab M, Timmins P, Nock V, Lehr T. Significant impact of time-of-day variation on metformin pharmacokinetics. Diabetologia. 2023. doi:10.1007/s00125-023-05898-4

Dings C, Götz KM, Och K, Sihinevich I, Werthner Q, Smola S, Bliem M, Mahfoud F, Volk T, Kreuer S, Rissland J, Selzer D, Lehr T. Model-based analysis of SARS-CoV-2 infections, hospitalization and outcome in Germany, the federal states and districts. Viruses. 2022. doi:10.3390/v14102114

Dings C, Meiser P, Holzer F, Flegel M, Selzer D, Nagy E, Mösges R, Klussmann JP, Lehr T. Pharmacometric modeling of the impact of azelastine nasal spray on SARS-CoV-2 viral load and related symptoms in COVID-19 patients. Pharmaceutics. 2022. doi:10.3390/pharmaceutics14102059

Scherer N, Kurbasic A, Dings C, Mari A, Nock V, Hennige AM, Koivula RW, Laakso M, Siloaho M, McDonald TJ, Pavo I, Giordano GN, Hansen TH, Rutters F, Dekker JM, Jablonka B, Ruetten H, Pearson ER, Franks PW, Lehr T. The impact and correction of analysis delay and variability in storage temperature on the assessment of HbA1c from dried blood spots -  an IMI DIRECT Study. Int J Proteom Bioinform 2019;4(1):7-13.

Scherer N, Dings C, Böhm M, Laufs U, Lehr T. Alternative treatment regimens with the PCSK9 inhibitors alirocumab and evolocumab: A pharmacokinetic and pharmacodynamic modeling approach. Journal of Clinical Pharmacology. 2017. doi:10.1002/jcph.866

Dings C, Scherer N, Freijer J, Nock V, Lehr T. Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: a DIRECT study. 26th Population Approach Group Europe (PAGE) meeting, 2017, Budapest, Hungary.

Dings C, Lehr T. Pharmacokinetic/pharmacodynamic modeling of acetylsalicylic acid and its major metabolite salicylic acid. 25th Population Approach Group Europe (PAGE) meeting, 2016, Lisbon, Portugal.

Dings C, Schäftlein A, Lehr T. Predicting the impact of oral anticoagulants on the human coagulation pathway using a comprehensive systems pharmacology model. Annual meeting of the German Pharmaceutical Society (DPhG), 2014, Frankfurt (Main), Germany.